Synthego Corporation vs Agilent Technologies, Inc.

Patent Owner's Notice of Appeal

Proof of Service for Notice of Appeal

Final Written Decision

Other: Hearing transcript

EXPUNGED

Synthego Corporation’s Oral Argument Presentation

Agilent Technologies Oral Argument Presentation

Joint Stipulation Regarding Service of Demonstratives

Updated Power of Attorney

Updated Mandatory Notice

Joint Stipulation Regarding Service of Demonstratives

Joint Response to the Board’s Order Regarding Conduct of Proceeding

EXPUNGED

Order: Setting Oral Argument

Conduct of Proceeding 37 C.F.R. § 42.5

Petitioner Synthego Corporation's Request for Oral Argument Pursuant to 37 C.F.R. Section 42.70(a)

Patent Owner's Request for Oral Argument

Motion to Seal Portions of Patent Owner's Sur-Reply Brief

Patent Owner's Sur-Reply [Redacted Version]

Patent Owner's Sur-Reply

Patent Owner's Objections to Evidence

Joint Motion to Seal

Petitioner's Reply to Patent Owner's Response - Confidential Version

Petitioner's Reply to Patent Owner's Response - Redacted Version

EX1047

EX1048

EX1049

EX1050

EX1051

EX1052

EX1053 - Confidential Version

EX1053 - Redacted Version

EX1054 - Confidential Version

EX1054 - Redacted Version

EX1055 - Confidential Version

EX1055 - Redacted Version

EX1056 - Confidential Version

EX1056 - Redacted Version

EX1057 - Confidential Version

EX1057-Redacted Version

EX1058 - Confidential Version

EX1058 - Redacted Version

EX1059

EX1060

EX1061

EX1062

EX2030 (Corrected)

EX2032 (Corrected)

Petitioner Synthego Corporation's Supplemental Power of Attorney for Edward R. Reines

Petitioner Synthego Corporation's Supplemental Mandatory Notice Adding Backup Counsel Under 37 C.F.R. Section 42.8(a)(3)

ORDER Conditionally Granting Petitioners Unopposed Motions for Pro Hac Vice Admission of Edward R. Reines 37 C.F.R. sec 42.10

Petitioner Synthego Corporation's Notice of Deposition of Dr. William S. Marshall

Petitioner Synthego Corporation's Motion for Admission Pro Hac Vice of Edward R. Reines Pursuant to 37 C.F.R. Section 42.10

Petitioner Synthego Corporation's Updated Exhibit List

Ex. 1044 - Reines Decl SIO PHV Mtn

Ex. 1045 - In Re Reines, 14-MA004 (14-4) (Fed. Cir. 2014-11-05)

Ex. 1046 - Reines Personal Statement (Fed. Cir. 14-4) (421)

Petitioner Synthego Corporation's Notice of Deposition of Dr. Jeffrey R. Sampson

Order: on Motion

PATENT OWNER���S UNOPPOSED MOTION FOR PRO HAC VICE ADMISSION OF DENISE DE MORY

EX2001

Petitioner's Evidentiary Objections to Exhibits Filed with Patent Owner's Response

Patent Owner Response

Patent Owner's Corrected Response

EX2021

EX2023

EX2024

EX2026

EX2027

EX2028

EX2029

EX2031

EX2031

EX2034

EX2035

EX2036

EX2037

EX2038

EX2039

EX2040

EX2041

EX2042

EX2043

EX2044

EX2045

EX2046

EX2047

EX2048

EX2049

EX2050

EX2051

EX2052

EX2053

EX2054

EX2055

EX2056

EX2057

EX2060

EX2061

EX2058

EX2059

EX2033

EX2062

EX2025

EX2063

Patent Owner's Notice of Deposition of Henry Morrice Furneaux

Joint Scheduling Stipulation Regarding Due Dates 1-3

Patent Owner's Objections to Evidence

Institution Decision Granting Institution of Inter Partes Review

Scheduling Order

Patent Owner's Sur-Reply

EX2011

EX2013

EX2018

EX2020

Patent Owner's Updated Mandatory Notice

Petitioner's Reply to Patent Owner's Preliminary Response

Patent Scheduling Order in 5:21-cv-07801-EJD

EX1043_LexMachina Time to Trial, Judge Davila Lifetime

EX2007

EX2007 (Part 2/4)

EX2007 (Part 3/4)

EX2007 (Part 4/4)

EX2008

EX2009

EX2010

EX2011

EX2012

EX2013

EX2014

EX2015

EX2016

EX2017

EX2019

Patent Owner's Preliminary Response

EX2003

EX2004

EX2005

EX2006

Order: Conduct of Proceeding 37 C.F.R. sec. 42.5

Exhibit 3001

Patent Owner's Mandatory Notice

Patent Owner's Power of Attorney

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

Petition for Inter Partes Review of U.S. Patent No. 10,337,001

U.S. Patent No. 10,337,001

Petitioner Synthego Corporation's Power of Attorney

Prosecution File History of U.S. Patent No. 10,337,001

Prosecution File History of U.S. Patent No. 10,337,001

Prosecution File History of U.S. Patent No. 10,337,001

Declaration of Dr. Henry Morrice Furneaux

Curriculum Vitae of Dr. Henry Morrice Furneaux

Ayal Hendel et al., Chemically Modified Guide RNAs Enhance CRISPR-Cas Genome Edition in Human Primary Cells, 33 Nature Biotechnology, 985-989 (2015)

WO 2015/026885 A1

Glen F. Deleavey & Masad J. Damha, Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing, 19 Chemistry & Biology, 937-954 (2012)

Jennifer A. Doudna and Emmanuelle Charpentier et al., Genome Editing, The New Frontier Of Genome Engineering with CRISPR-Cas9, 346 Science 6213, 1258096-1 - 1258096-9 (2014)

Jan Krutzfeldt et al., Specificity, Duplex Degradation and Subcellular Localization of Antagomirs, 35 Nucleic Acids Research, 2885-2892 (2007)

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

EXPUNGED

Richard N. Threlfall et al., Synthesis of Biological Activity of Phosphonoacetate- and Thiophosphonoacetate-Modified 2'-O-Methyl Oligoribonucleotides, 10 Organic & Biomolecular Chem., 746-754 (2012)

Byong Hoon Yoo et al., 2'-O-methyl Modified Phosphorothioate Antisense Oligonucleotides have Reduced Non-Specific Effects In Vitro, 32 Nucleic Acids Research, 2008-2016 (2004)

Jurgen Soutschek et. al., Therapeutic Silencing of an Endogenous Gene by Systemic Administration of Modified siRNAs, 432 Nature, 173-178 (2004)

Patrick D Hsu et al., DNA Targeting Specificity of RNA-guided Cas9 Nucleases, 31 Nature Biotechnology 827-832 (2013)

Mitchell O'Connell et al., Programmable RNA Recognition and Cleavage by CRISPR-Cas9, 516 Nature, 263-266 (2014)

GE Edit-R Flyer, gelifesciences.com/dharmacon

Sojung Kim et al., Highly Efficient RNA-guided Genome Editing in Human Cells Via Delivery of Purified Cas9 ribonucleoproteins, 24 Genome Research, 1012-1019 (2014)

Ophir Shalem et al., Genome-Scale CRISPR-Cas9 Knockout, 343 Science, 84-87 (2014)

Tim Wang et al., Genetic Screens in Human Cells Using the CRISPR-Cas9 System, 343 Science, 80-84 (2014)

U.S. Patent Pub. No. 2017/0166893 A1 (Doudna et al.)

U.S. Patent Pub. No. 2015/0232881 A1 (Glucksmann et al.)

Intentionally Omitted

U.S. Patent Pub. No. 2015/0071889 A1 (Musunuru et al.)

EP 3835419 A1 (Doudna et al.)

Kim A. Lennox and Mark A. Behlke, A Direct Comparison of Anti-microRNA Oligonucleotide Potency, 27 Pharm Res., 1788-1799 (2010)

Fritz Eckstein, Phosphorothioates, Essential Components of Therapeutic Oligonucleotides, 24 Nucleic Acid Therapeutics, 374-387 (2014)

Hiroshi Nishimasu et al., Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA, 156 Cell, 935 (2014)

John Timmer, "Bacterial Immune System used to Engineer Human DNA in Human Cells," https://arstechnica.com/science/2013/01/bacterial-immune-system-used-to-engineer-human-dna-in-human-cells/

Anne Trafton, "New Method for Turning Genes On and Off Could Enable More Complex Synthetic Biology Circuits," https://news.mit.edu/2013/an-easier-way-to-control-genes-0903

Matthew Herper, "[CRISPR/Cas9] Is Spreading Like Wildfire from Everyone Who Knows About It and It Certainly is Very Tantalizing," https://www.forbes.com/sites/matthewherper/2013/03/19/the-protein-that-could-change-biotech-forever/?sh=15f215a32063

Jan Krutzfeldt et al., Silencing of microRNAs in vivo with 'antagomirs', 438 Nature, 685-689 (2005)

WO 2008/091703 A2 (Stoffel et al.)

Bret P. Monia et al., Evaluation of 2'-modified Oligonucleotides Containing 2'-deoxy Gaps as Antisense Inhibitors of Gene Expression, 268 J. Biol. Chem., 14514 (1993)

Yanfang Fu et al., Improving CRISPR-Cas Nuclease Specificity Using Truncated Guide RNAs, 32 Nat Biotechnology, 279-284 (2014)

Wenyan Jiang et al., RNA-guided Editing of Bacterial Genomes Using CRISPR-Cas Systems, 31 Nat Biotechnology, 233-239 (2013)

Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, 337 Science, 816-821 (2012)

Neville Sanjana et al., Improved Vectors and Genome-wide Libraries for CRISPR Screening, 11 Nature Methods, 783-784 (2014)

Hiroko Koike-Yusa et al., Genome-wide Recessive Genetic Screening in Mammalian Cells with a Lentiviral CRISPR-Guide RNA Library, 32 Nat Biotechnology, 267-273 (2014)

Yuexin Zhou et al., High-throughput Screening of a CRISPR/Cas9 Library for Functional Genomics in Human Cells, 509 Nature, 487-491 (2014)

Luke A. Gilbert et al., Genome-scale CRISPR-mediated control of gene repression and activation, 159 Cell, 647-661 (2014)

2' O-methyl RNA (2' me) synthesis, 2' O-Methyl RNA, 2'OMe RNA Synthesis, https://www.biosyn.com/oligonucleotideproduct/2-o-methyl-rna-2-ome-rna-synthesis.aspx

Phosphorothioate DNA synthesis, Phosphorothioate DNA Synthesis Modification, https://www.biosyn.com/oligonucleotideproduct/phosphorothioate-dna-synthesis-modification.aspx#